InvestSMART

Arovella Therapeutics Limited (ASX:ALA)

ALERT: Price-sensitive ASX Announcement for ALA
Current share price for ALA : $0.067 -0.03 (-30.93%)+
Announcement
Release
2 Oct 2025 9:48AM
Price at Release
$0.097
Full Release
download
Summary
Arovella Therapeutics Limited announced the success of their novel CLDN18.2-targeting chimeric antigen receptor (CAR) T cells in eliminating pancreatic cancer cells. This was demonstrated in a proof-of-concept in vitro study using the human pancreatic adenocarcinoma cell line PaTu8892S, which naturally expresses CLDN18.2. The study confirmed the potent activity of Arovella's CLDN18.2 CAR against pancreatic cancer cells, achieving results comparable to a leading CLDN18.2 CAR currently under regulatory review in China. Arovella is further developing its CAR-iNKT cell platform, integrating the CLDN18.2 CAR to target both pancreatic and gastric cancers. The company is one of the few developing a CLDN18.2-targeting CAR-iNKT cell product, aiming to advance to in vivo studies in mice. The results of this study support the potential superiority of CLDN18.2-CAR-iNKT cells due to their additional functionality within the tumour microenvironment.
Key Points
  • Arovella's CLDN18.2 CAR demonstrated robust elimination of pancreatic cancer cells.
  • The study used the PaTu8892S cell line, showing potent activity of the CLDN18.2 CAR.
  • Arovella will incorporate the CLDN18.2 CAR into their iNKT cell platform.
  • Upcoming in vivo studies will target pancreatic and gastric cancers.
  • The CLDN18.2 CAR-iNKT cells are expected to outperform CAR-T cells.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.